GlassScriptPhysician profile
Gentry S Caton
NPI 1922235951
$2,963.27
in general payments reported to CMS, 2019-2025
33 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $365 · 2021: $55.76 · 2022: $416 · 2023: $151 · 2024: $476 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322 · Education: $22.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.42 |
| Education | $22.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,385.98 | 2019-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $199.83 | 2022-2024 | Interstim, Pillcam |
| Abbvie INC. | $138.55 | 2020-2025 | |
| Genzyme Corporation | $111.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.63 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $72.76 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $72.16 | 2025 | Ibsrela |
| Celltrion USA INC. | $70.28 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $69.27 | 2025 | Omvoh, Zepbound |
| Ethicon US, LLC | $65.28 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $64.33 | 2020-2024 | Dificid |
| Vertex Pharmaceuticals Incorporated | $60.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.35 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $51.09 | 2024 | |
| Smith+Nephew, INC. | $41.60 | 2019-2024 | Grafix Pl, Stravix, Collagenase Santyl |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.70 | 2019-2020 | |
| Cook Medical LLC | $39.33 | 2020 | |
| Phathom Pharmaceuticals, INC. | $38.03 | 2025 | Voquezna |
| Novo Nordisk INC | $38.02 | 2025 | Wegovy |
| Becton, Dickinson and Company | $33.70 | 2024 | Venclose Maven Catheter |
| Regeneron Healthcare Solutions, INC. | $31.97 | 2025 | Dupixent |
| Daiichi Sankyo INC. | $21.39 | 2023 | Injectafer |
| Myriad Genetic Laboratories, INC. | $20.94 | 2024 | Myrisk |
| Janssen Biotech, INC. | $19.91 | 2025 | Tremfya |
| Cardiovascular Systems INC. | $17.21 | 2019 | |
| Vioptix INC | $16.53 | 2020 | |
| Abbott Laboratories | $15.96 | 2024 | Jeti All In One Non-Sterile Kit |
| Qol Medical, LLC | $15.13 | 2025 | Sucraid |
| Bard Peripheral Vascular, INC. | $14.77 | 2019 | |
| Covidien LP | $14.31 | 2020 | |
| Braintree Laboratories, INC. | $14.07 | 2024 | Sutab, Suflave |
| Acell, INC. | $13.21 | 2019 | |
| Cashflow Solutions, LLC | $11.12 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gentry Caton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.